Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT01585688 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01585688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01585688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2012
Completion date
October 31, 2017
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, non-hodgkin's lymphoma